Monoclonal gammopathy of undetermined significance (MGUS)

Request an Appointment
Print

Departments and specialties

Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, Florida and Minnesota. Staff skilled in dozens of specialties work together to ensure quality care and successful recovery.

Departments that treat this condition

Research

Researchers at Mayo Clinic coined the term monoclonal gammopathy of undetermined significance (MGUS). They have been studying the disorder for decades.

The focus is on finding risk factors for getting the condition, how these risk factors might affect treatment, and how to prevent MGUS from leading to blood cancers and other conditions.

Doctors and scientists in the Hematologic Malignancies Program of the Mayo Clinic Comprehensive Cancer Center are working on improving the diagnosis and treatment of myeloma and other blood disorders.

Publications

See a list of publications on monoclonal gammopathy of undetermined significance (MGUS) by Mayo Clinic doctors on PubMed, a service of the National Library of Medicine.

By Mayo Clinic Staff

Monoclonal gammopathy of undetermined significance (MGUS) care at Mayo Clinic

Request an appointment
Diagnosis & treatmentCare at Mayo Clinic
Sept. 10, 2024
Print

Living with monoclonal gammopathy of undetermined significance (mgus)?

Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community.

Blood Cancers & Disorders Discussions

See more discussions

Related

Associated Procedures

Products & Services

Monoclonal gammopathy of undetermined significance (MGUS)

Research: It's all about patients

[MUSIC PLAYING]

Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight.